Management of overt hepatic encephalopathy

Journal of Clinical and Experimental Hepatology

Volumn 5, Issue S1, 2015, Pages S82-S87

  Sharma, Praveen ^a   Sharma, Barjesh C ^b  

^a SIR GANGA RAM HOSPITAL   (India)

^b G B PANT HOSPITAL   (India)

Author keywords

Disaccharides; HE; Hepatic encephalopathy; HR; Lactulose; MHE; TIPS

Indexed keywords

BENZOIC ACID; BRANCHED CHAIN AMINO ACID; DISACCHARIDE; LACTITOL; LACTULOSE; NEOMYCIN; NON ABSORBABLE DISACCHARIDE; ORNITHINE ASPARTATE; PAROMOMYCIN; PROBIOTIC AGENT; RIFAXIMIN; UNCLASSIFIED DRUG;

ANTIMICROBIAL THERAPY; CHEMOPROPHYLAXIS; COMBINATION CHEMOTHERAPY; DIET THERAPY; DRUG EFFICACY; DRUG MECHANISM; HEPATIC ENCEPHALOPATHY; HUMAN; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; REVIEW; SECONDARY PREVENTION;

EID: 84924578302     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/j.jceh.2014.04.004     Document Type: Review

References (50)

1. Ferenci P., Lockwood A., Mullen K., Tarter R., Weissenborn K., Blei A.T. Hepatic encephalopathy - definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002, 35:716-721.
2. Riordan S.M., Williams R. Treatment of hepatic encephalopathy. NEngl J Med 1997, 337:473-479.
3. Poordad F.F. Review article: the burden of hepatic encephalopathy. Aliment Pharmacol Ther 2007, 25(suppl 1):3-92.
4. Bajaj J.S., Wade J.B., Sanyal A.J. Spectrum of neurocognitive impairment in cirrhosis: implications for the assessment of hepatic encephalopathy. Hepatology 2009, 50(6):2014-2021.
5. Bajaj J.S., Cordoba J., Mullen K.D., et al. Review article: the design of clinical trials in hepatic encephalopathy-an International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN) consensus statement. Aliment Pharmacol Ther 2011 Apr, 33(7):739-747. International Society for Hepatic Encephalopathy and Nitrogen Metabolism (ISHEN).
6. Albrecht J., Zielińska M., Norenberg M.D. Glutamine as a mediator of ammonia neurotoxicity: a critical appraisal. Biochem Pharmacol 2010, 80(9):1303-1308.
7. Bismuth M., Funakoshi N., Cadranel J.F., Blanc P. Hepatic encephalopathy: from pathophysiology to therapeutic management. Eur J Gastroenterol Hepatol 2011, 23(1):8-22.
8. Lockwood A., Yap E., Wong W. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. JCereb Blood Flow Metab 1991, 11:337-341.
9. Häussinger D., Kircheis G., Fischer R., Schliess F., vom Dahl S. Hepatic encephalopathy in chronic liver disease: a clinical manifestation of astrocyte swelling and low grade cerebral edema. JHepatol 2000, 32:1035-1038.
10. Blei A.T., Cordoba Hepatic encephalopathy. Am J Gastroenterol 2001, 96:1968-1976.
11. Clausen M.R., Mortensen P.B. Lactulose, disaccharides and colonic flora: clinical consequences. Drugs 1997, 53(6):930-942.
12. Cordóba J., Blei A.T. Treatment of hepatic encephalopathy. Am J Gastroenterol 1997, 92(9):1429-1439.
13. Simmons F., Goldstein H., Boyle J.D. Acontrolled clinical trial of lactulose in hepatic encephalopathy. Gastroenterology 1970, 59:827-832.
14. Uribe M., Campollo O., Vargas F., Ravelli G.P., Mundo F., Zapata L. Acidifying enemas (lactitol and lactose) vs. nonacidifying enemas (tap water) to treat acute portal-systemic encephalopathy: a double-blind, randomized clinical trial. Hepatology 1987, 7:639-643.
15. Lanthier P.L., Morgan M.Y. Lactitol in the treatment of chronic hepatic encephalopathy: an open comparison with lactulose. Gut 1985, 26:415-420.
16. Heredia D., Terés J., Orteu N., Rodés J. Lactitol vs. lactulose in the treatment of chronic recurrent portal-systemic encephalopathy. JHepatol 1988, 7(1):106-110.
17. Riggio O., Balducci G., Ariosto F., et al. Lactitol in prevention of recurrent episodes of hepatic encephalopathy in cirrhotic patients with portal-systemic shunt. Dig Dis Sci 1989, 34(6):823-829.
18. Blanc P., Daures J.P., Rouillon J.M., et al. Lactitol or lactulose in the treatment of chronic hepatic encephalopathy: results of a meta-analysis. Hepatology 1992, 15(2):222-228.
19. Cammà C., Fiorello F., Tinè F., Marchesini G., Fabbri A., Pagliaro L. Lactitol in treatment of chronic hepatic encephalopathy. A meta-analysis. Dig Dis Sci 1993, 38(5):916-922.
20. Als-Nielsen B., Gluud L.L., Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004, 328(7447):1046.
21. Sharma P., Sharma B.C. Profile of hepatic encephalopathy in children with cirrhosis and response to lactulose. Saudi J Gastroenterol 2011, 17(2):138-141.
22. Sharma P., Sharma B.C., Sarin S.K. Predictors of nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy. Eur J Gastroenterol Hepatol 2010, 22(5):526-531.
23. Conn H.O., Leevy C.M., Vlacevic Z.R., Rodgers J.B., Maddrey W.C., Seef L. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy. A double blind controlled trial. Gastroenterology 1997, 72:573-583.
24. Atterbury C.E., Maddrey W.C., Conn H.O. Neomycin-sorbitol and lactulose in the treatment of acute portal-systemic encephalopathy. A controlled, double-blind clinical trial. Am J Dig Dis 1978, 23:398-406.
25. Orlandi F., Freddara U., Candelaresi M.T., Morettini A., Corazza G.R., Di Simone A. Comparison between neomycin and lactulose in 173 patients with hepatic encephalopathy: a randomized clinical study. Dig Dis Sci 1981, 26:498-506.
26. Mullen K., Prakash R. Rifaximin for the treatment of hepatic encephalopathy. Expert Rev Gastroenterol Hepatol 2010, 4(6):665-677.
27. Festi D., Mazzella G., Orsini M. Rifaximin in the treatment of chronic hepatic encephalopathy: results of a multicenter study of efficacy and safety. Curr Ther Res 1993, 54(5):598-609.
28. Massa P., Vallerino E., Dodero M. Treatment of hepatic encephalopathy with rifaximin: double blind, double dummy study versus lactulose. Eur J Clin Res 1993, 4:7-18.
29. Mas A., Rodes J., Sunyer L., Rodrigo L., Planas R., Vargas V. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. JHepatol 2003, 38:51-58.
30. Paik Y.H., Lee K.S., Han K.H., et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J 2005, 46(3):399-407.
31. Jiang Q., Jiang X.H., Zheng M.H., Jiang L.M., Chen Y.P., Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis. Eur J Gastroenterol Hepatol 2008, 20(11):1064-1070.
32. Eltawil K.M., Laryea M., Peltekian K., Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J Gastroenterol 2012, 18(8):767-777.
33. Di Piazza S., Filippazzo M.G., Valenza L.M., et al. Rifaximine versus neomycin in the treatment of portosystemic encephalopathy. Ital J Gastroenterol 1991, 23:403-407.
34. Parini P., Cipolla A., Ronchi M., Salzetta A., Mazzella G., Roda E. Effect of rifaximin and paromomycin in the treatment of portal-systemic encephalopathy. Curr Ther Res Clin Exp 1992, 52:34-39.
35. Pedretti G., Calzetti C., Missale G., Fiaccadori F. Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 1991, 23:175-178.
36. Loguercio C., Abbiati R., Rinaldi M., Romano A., Del Vecchio Blanco C., Coltorti M. Long-term effects of Enterococcus faecium SF68 versus lactulose in the treatment of patients with cirrhosis and grade 1-2 hepatic encephalopathy. JHepatol 1995, 23(1):39-46.
37. Loguercio C., Del Vecchio Blanco C., Coltorti M. Enterococcus lactic acid bacteria strain SF68 and lactulose in hepatic encephalopathy: a controlled study. JInt Med Res 1987, 15(6):335-343.
38. McGee R.G., Bakens A., Wiley K., Riordan S.M., Webster A.C. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst Rev 2011, 9(11):CD008716.
39. Sushma S., Dasarathy S., Tandon R.K., Jain S., Gupta S., Bhist M.S. Sodium benzoate in the treatment of acute hepatic encephalopathy: a double-blind randomized trial. Hepatology 1992, 16(1):138-144.
40. Eriksson L.S., Persson A., Wahren J. Branched-chain amino acids in the treatment of chronic hepatic encephalopathy. Gut 1982 Oct, 23(10):801-806.
41. Gluud L.L., Dam G., Borre M., et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-analyses of randomized controlled trials. JNutr 2013 Aug, 143(8):1263-1268.
42. Kircheis G., Nilius R., Held C., et al. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1998, 25:1351-1360.
43. Bai M., Yang Z., Qi X., Fan D., Han G. L-ornithine-L-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials. JGastroenterol Hepatol 2013 May, 28(5):783-792.
44. Amodio P., Bemeur C., Butterworth R., et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 2013 Jul, 58(1):325-336.
45. Mohammad R.A., Regal R.E., Alaniz C. Combination therapy for the treatment and prevention of hepatic encephalopathy. Ann Pharmacother 2012 Nov, 46(11):1559-1563.
46. Sharma B.C., Sharma P., Lunia M.K., Srivastava S., Goyal R., Sarin S.K. Arandomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol 2013 Sep, 108(9):1458-1463.
47. Sharma B.C., Sharma P., Agrawal A., Sarin S.K. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 2009 Sep, 137(3):885-891.
48. Riggio O., Masini A., Efrati C., et al. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study. JHepatol 2005, 42:674-679.
49. Bass N.M., Mullen K.D., Sanyal A., et al. Rifaximin treatment in hepatic encephalopathy. NEngl J Med 2010 Mar 25, 362(12):1071-1081.
50. Agrawal A., Sharma B.C., Sharma P., Sarin S.K. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012 Jul, 107(7):1043-1050.